Acme United (ACU) Q2 2026 earnings review
Strong Rebound as Top-Line Accelerates and Earnings Reverse Q1 Slump
Acme United delivered a robust 26Q2, fully reversing the profitability shock of Q1. Net sales are accelerating, up 16% YoY to $62.7M, fueled by the My Medic acquisition and a recovery in the core Westcott business. Crucially, the volume growth flowed to the bottom line this time: Net Income grew 6% YoY to $5.1M, recovering from a 40% collapse in the prior quarter. Gross margins expanded to 42.6% due to the direct-to-consumer mix of My Medic. While tariffs remain a headwind, management executed effectively on its strategic pivots.
🐂 Bull Case
Excluding the My Medic acquisition, comparable sales still grew a healthy 8%. The Westcott cutting tools segment returned to growth (+8%), proving that the 2025 promotional freeze by retailers has thawed.
Gross margin expanded 160 basis points to 42.6%, demonstrating that the shift toward higher-margin DTC sales (My Medic) is successfully offsetting higher U.S. import tariffs.
🐻 Bear Case
Despite margin expansion at the consolidated level, U.S. margins continue to be burdened by inventory purchased at elevated tariff levels. This macro headwind will persist, albeit at a decreasing rate.
The Canadian segment decelerated aggressively to just 1% USD growth (+3% local), a sharp contrast to the 14-16% growth rates seen in 2025. This lagging segment requires close monitoring.
⚖️ Verdict: 🟢
Bullish. The company successfully absorbed the margin shock of Q1. Accelerating organic growth combined with accretive M&A and strong free cash flow generation paints a compelling recovery narrative.
Key Themes
My Medic Acquisition Fueling Growth and Margins
The January acquisition of My Medic contributed half of the quarter's 16% total revenue growth. As a direct-to-consumer tactical and trauma product line, it carries structurally higher margins, which directly drove the consolidated gross margin up to 42.6%. Management is leveraging Acme's scale to lower My Medic's product costs while expanding its industrial and retail customer base.
Westcott Retail Recovery
Westcott cutting tools saw net sales grow 8% in Q2. This represents a critical reversing trend from 2025, when high tariffs caused retailers to abandon back-to-school promotional activity. The return of normal retail demand and promotional activity for these specific products removes a major anchor from U.S. segment growth.
European E-commerce Acceleration
The European segment is accelerating rapidly, with Q2 net sales surging 24% in USD (19% local currency). Management specifically cited higher e-commerce sales and the October 2025 acquisition of a German cutting/sharpening line as the primary growth engines, proving the success of their digital and bolt-on M&A strategies abroad.
Lingering Tariff Headwinds on U.S. Margins
Macro picture remains challenged by trade policy. Management noted that U.S. gross margins were still affected by products purchased at peak tariff levels. While the shock is decelerating compared to Q1's 40% net income collapse, tariffs will continue pressuring unit economics in the coming quarters, limiting maximum operating leverage.
Canada Segment Abruptly Decelerating
A clear laggard emerged: Canadian net sales grew only 1% in USD (3% local currency) in Q2. This contradicts the overall accelerating narrative and marks a severe slowdown from the 16% growth seen in 26Q1 and 14% in 25Q4. If first-aid product momentum has stalled in Canada, a key geographic growth pillar is compromised.
Elevated SG&A Run-Rate
Selling, general, and administrative expenses increased to $19.9M in Q2, up 26% YoY, outpacing the 16% revenue growth. While partly a mechanical result of integrating the advertising-heavy DTC My Medic business, the lack of SG&A leverage highlights the execution risk in management's plan to 'drive growth on a lower cost base' for the acquired asset.
Other KPIs
Accelerating/Expanding. Up from 41.0% a year ago and 39.7% in 26Q1. This confirms that the high-margin DTC revenue from My Medic is successfully diluting the negative margin impact of legacy inventory purchased during peak tariff periods.
Stable and highly cash generative. This strong conversion allowed Acme to digest the $14.5M cash outlay for My Medic, pay $2.4M in dividends, and absorb a new $1.6M German product line while only increasing net bank debt by $4.5M YoY ($27.3M vs $22.8M).
Guidance
Management explicitly stated that the seasonal DTC nature of My Medic means it had minimal earnings impact in H1 2026, but is expected to generate the majority of its profitability in the fourth quarter. This implies strong earnings acceleration into year-end.
No specific numerical guidance was provided for FY26. However, management expects prior high tariffs to continue pressuring margins, but explicitly noted this will occur at a 'decreasing rate' in coming quarters.
Key Questions
Canada Deceleration
Canadian growth slowed abruptly to 1% in USD this quarter after double-digit growth in prior periods. Is this a timing issue with first-aid restocking, or are we seeing a structural normalization in Canadian demand?
SG&A Leverage Timing
SG&A grew 26% YoY, outpacing sales growth of 16%. How much of this is structural to My Medic's DTC customer acquisition costs, and when should investors expect to see operating leverage materialize?
My Medic B2B Progress
You mentioned aggressively presenting My Medic products to industrial and retail customers. What is the early feedback, and what percentage of My Medic's Q4 peak revenue do you expect to come from B2B channels versus its legacy DTC channel?